四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00460 四环医药

交易中 07-23 10:11:47

0.560

+0.000

0.00%

最高0.560	最低0.550	成交量133.70万
今开0.550	昨收0.560	日振幅1.79%
总市值52.19亿	流通市值52.19亿	总股本93.20亿
成交额73.57万	换手率0.01%	流通股本93.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00460","market":"HK","secType":"STK","nameCN":"四环医药","latestPrice":0.56,"timestamp":1721700698698,"preClose":0.56,"halted":0,"volume":1337000,"delay":0,"floatShares":9319999206,"shares":9319999206,"eps":-0.0062204157,"marketStatus":"交易中","marketStatusCode":2,"change":0,"latestTime":"07-23 10:11:47","open":0.55,"high":0.56,"low":0.55,"amount":735700,"amplitude":0.017857,"askPrice":0.56,"askSize":2497000,"bidPrice":0.55,"bidSize":1643000,"shortable":3,"etf":0,"ttmEps":-0.0062204159218116955,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1721707200000},"adr":0,"adjPreClose":0.56,"dividendRate":0.061598,"openAndCloseTimeList":[[1721698200000,1721707200000],[1721710800000,1721721600000]],"volumeRatio":1.84752,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/00460","defaultTab":"news","newsList":[{"id":"2452171774","title":"四环医药07月18日主力资金流入42万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452171774","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452171774?lang=zh_cn&edition=full","pubTime":"2024-07-18 16:16","pubTimestamp":1721290618,"startTime":"0","endTime":"0","summary":"07月18日，四环医药股价收平报0.56元，成交金额472万元，换手率0.09%，振幅3.57%，量比1.02。四环医药今日主力资金净流入42万元，连续3日净流入，上一交易日主力净流入28万元，今日环比增加50.00%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为60.00%，平均涨幅为3.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071816172295d42f32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071816172295d42f32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00460","BK1600","BK1515","BK1593"],"gpt_icon":0},{"id":"2450872040","title":"南向资金7月10日净卖出四环医药107.60万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2450872040","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450872040?lang=zh_cn&edition=full","pubTime":"2024-07-11 09:31","pubTimestamp":1720661490,"startTime":"0","endTime":"0","summary":"7月10日，南向资金减持四环医药107.60万股连续5日减持。截止当日收盘，港股通共持有四环医药83589.70万股，占流通股8.95%。四环医药近5个交易日上涨3.77%，港股通累计减持455.20万股；近20个交易日上涨3.77%，港股通累计减持4672.30万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071109422595a2b823&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071109422595a2b823&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1600","BK1515","BK1593","00460","BK1191"],"gpt_icon":0},{"id":"2450055656","title":"南向资金7月8日净卖出四环医药28.50万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2450055656","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450055656?lang=zh_cn&edition=full","pubTime":"2024-07-09 09:31","pubTimestamp":1720488682,"startTime":"0","endTime":"0","summary":"7月8日，南向资金减持四环医药28.50万股连续3日减持。截止当日收盘，港股通共持有四环医药83802.70万股，占流通股8.98%。港股通减持金额前五个股分别为美团-W、中国移动、中国海洋石油、快手-W、小鹏汽车-W。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407090941469593e4f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407090941469593e4f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1600","BK1191","00460"],"gpt_icon":0},{"id":"2448697876","title":"金格奖上榜公司：四环医药（0460.HK）荣获“格隆汇金格奖—ESG创新实践卓越企业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2448697876","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448697876?lang=zh_cn&edition=full","pubTime":"2024-07-02 08:56","pubTimestamp":1719881768,"startTime":"0","endTime":"0","summary":"荣获“格隆汇金格奖—ESG创新实践卓越企业”","market":"hk","thumbnail":"https://img7.gelonghui.com/column/5.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/5.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/822855","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1600","BK1515","ESG","BK1191","00460","BK1593"],"gpt_icon":0},{"id":"2446523202","title":"格隆汇·中期策略峰会·2024金格奖之“ESG创新实践卓越企业”奖项揭晓：第四范式(06682.HK)、四环医药(00460.HK)等20家企业上榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2446523202","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446523202?lang=zh_cn&edition=full","pubTime":"2024-06-28 14:33","pubTimestamp":1719556395,"startTime":"0","endTime":"0","summary":"奖项的获奖企业，以其创新精神和实践，展现了在ESG领域的领导力和开拓性。","market":"us","thumbnail":"https://img3.gelonghui.com/da638-11370621-7d57-4f05-9f2f-6192656e7902.jpg?guru_height=930&guru_width=1405","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/da638-11370621-7d57-4f05-9f2f-6192656e7902.jpg?guru_height=930&guru_width=1405"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/819481","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1593","02302","03611","BK1109","09880","06609","BK1515","BK0231","BK1152","03773","BK1128","00460","01167","ESG","BK1161","BK1183","BK1228","SG9999001069.SGD","BK1595","02438","09959","BK1191","02391","00382","01725","BK1100","BK1124","BK1574","06682","BK1600","BK1516","01969","BK1117","02265","01675","688031","BK1167","BK1556","BK1140","BK1575","BK1587","BK1518","BK1142"],"gpt_icon":0},{"id":"2446135245","title":"抢跑合成生物学领域，简析四环医药（0460.HK）在医美市场的创新和机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2446135245","media":"格隆汇","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446135245?lang=zh_cn&edition=full","pubTime":"2024-06-28 08:35","pubTimestamp":1719534940,"startTime":"0","endTime":"0","summary":"凭借着晶颜生物，四环医药成功卡位在合成生物学这一高速成长的赛道上","market":"hk","thumbnail":"https://img7.gelonghui.com/column/9.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/9.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/817639","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1515","BK1191","BK1600","BK1593","00460"],"gpt_icon":0},{"id":"2446373705","title":"四环医药羟苯磺酸钙胶囊获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2446373705","media":"新京报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446373705?lang=zh_cn&edition=full","pubTime":"2024-06-27 20:51","pubTimestamp":1719492686,"startTime":"0","endTime":"0","summary":"新京报讯（记者张兆慧）6月27日，四环医药发布公告称，非全资附属公司惠升生物研发的羟苯磺酸钙胶囊获批上市，此次获批视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙是一种毛细血管保护剂，用于改善微血管微循环，可以调节微血管壁的生理功能，增加通透性，降低阻力，降低血浆黏度，降低血小板的高聚集性，从而预防血栓形成，提高红细胞的柔韧性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406273115873084.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406273115873084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1515","BK1191","BK1593","00460","BK1600"],"gpt_icon":0},{"id":"2446377016","title":"四环医药盘中异动 快速下跌5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2446377016","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446377016?lang=zh_cn&edition=full","pubTime":"2024-06-27 13:20","pubTimestamp":1719465623,"startTime":"0","endTime":"0","summary":"2024年06月27日下午盘13时20分，四环医药股票出现异动，股价大幅下跌5.36%。截至发稿，该股报0.530港元/股，成交量751.1万股，换手率0.08%，振幅5.36%。四环医药股票所在的药品行业中，整体跌幅为0.32%。其相关个股中，中国同辐、泰凌医药、兆科眼科-B涨幅较大，振幅较大的相关个股有中国医疗集团、君圣泰医药-B、泰凌医药，振幅分别为14.68%、9.40%、8.57%。消息层面，截至13时20分，四环医药股票正面舆情新闻比例6.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240627132023941f1b19&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240627132023941f1b19&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2446377009","title":"四环医药(00460)下跌5.36%，报0.53元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446377009","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446377009?lang=zh_cn&edition=full","pubTime":"2024-06-27 13:20","pubTimestamp":1719465623,"startTime":"0","endTime":"0","summary":"6月27日，四环医药(00460)盘中下跌5.36%，截至13:20，报0.53元/股，成交409.24万元。四环医药控股集团有限公司是中国处方药市场的领先制药企业，主要业务为生产和销售心脑血管处方药物，自2007年起一直是全国最大的心脑血管处方药物供应商。公司的关键经营数据包括独特的销售模式、全国覆盖的销售网络、多元化的产品组合以及强大的研发能力。截至2023年年报，四环医药营业总收入18.61亿元、净利润-5401.7万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/27132041231256.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1600","BK1515","BK1191","00460","BK1593"],"gpt_icon":0},{"id":"2446309280","title":"四环医药旗下惠升生物：羟苯磺酸钙胶囊获批，2023年国内销售额达2.55亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446309280","media":"和讯网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446309280?lang=zh_cn&edition=full","pubTime":"2024-06-27 13:03","pubTimestamp":1719464625,"startTime":"0","endTime":"0","summary":"快讯正文四环医药宣布，其非全资附属公司惠升生物制药股份有限公司研发的羟苯磺酸钙胶囊已获得国家药品监督管理局颁发的药品注册证书，该产品通过仿制药质量和疗效一致性评价。该药物是中国临床指南推荐用于改善糖尿病微循环的药物，并被列入国家医保乙类药物。2021年中国糖尿病患者约1.4亿人，其中约20%~40%会发生糖尿病视网膜病变。据药智网数据，2023年羟苯磺酸钙口服制剂在国内公立医院的销售收入达到人民币2.55亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271511359f6ace0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406271511359f6ace0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00460","BK1515","BK1600","BK1593"],"gpt_icon":0},{"id":"2446374593","title":"四环医药(00460.HK)： 惠升生物研发的羟苯磺酸钙胶囊获准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446374593","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446374593?lang=zh_cn&edition=full","pubTime":"2024-06-27 12:22","pubTimestamp":1719462120,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布，公司旗下非全资附属公司惠升生物研发的羟苯磺酸钙胶囊已获内地国家药监局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙胶囊今次获批用于微血管病的治疗，如糖尿病性微血管病变-视网膜病及肾小球硬化症，微血管损伤等。(vc/a)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-26 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220413154448549_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220413154448549_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359661/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2446371449","title":"【港股通】四环医药(00460)：惠升生物研发的羟苯磺酸钙胶囊获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446371449","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446371449?lang=zh_cn&edition=full","pubTime":"2024-06-27 12:16","pubTimestamp":1719461783,"startTime":"0","endTime":"0","summary":"金吾财讯 | 四环医药(00460)公布，集团旗下非全资附属公司惠升生物研发的羟苯磺酸钙胶囊已获中国国家药监局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙是一种毛细血管保护剂，用于改善微血管微循环，可以调节微血管壁的生理功能，增加通透性，降低阻力，降低血浆黏度，降低血小板的高聚集性，从而预防血栓形成，提高红细胞的柔韧性。羟苯磺酸钙为中国临床指南推荐用于改善糖尿病微循环的药物。羟苯磺酸钙胶囊为国家医保乙类药物。该产品本次获批适应症为：用于微血管病的治疗，如糖尿病性微血管病变－视网膜病及肾小球硬化症，微血管损伤等。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZTI5ZTY0Zjc5ODE4NTM5ZmY3ZmNjMTZiNDQwNzE0NzU0NTE4MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTI5ZTY0Zjc5ODE4NTM5ZmY3ZmNjMTZiNDQwNzE0NzU0NTE4MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939410","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HSCEI","BK1593","07226","BK1515","YANG","BK1600","HSTECH","00460","BK1191"],"gpt_icon":0},{"id":"2446374817","title":"四环医药：附属公司羟苯磺酸钙胶囊获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2446374817","media":"界面","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446374817?lang=zh_cn&edition=full","pubTime":"2024-06-27 12:13","pubTimestamp":1719461599,"startTime":"0","endTime":"0","summary":"四环医药6月27日在港交所公告，集团旗下非全资附属公司惠升生物制药股份有限公司研发的羟苯磺酸钙胶囊已获国家药品监督管理局颁发的药品注册证书，可视同通过仿制药质量和疗效一致性评价。羟苯磺酸钙胶囊为国家医保乙类药物。该产品本次获批适应症为：用于微血管病的治疗，如糖尿病性微血管病变-视网膜病及肾小球硬化症，微血管损伤等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240627121319aef6d88d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240627121319aef6d88d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1515","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2446822330","title":"港股异动 | 四环医药(00460)涨近4% 旗下新型抗血栓形成药替格瑞洛分散片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446822330","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446822330?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:22","pubTimestamp":1719386560,"startTime":"0","endTime":"0","summary":"据悉，替格瑞洛是一种新型抗血栓形成药，具有强效抗血小板聚预防血栓形成的作用。此外，四环医药近日宣布，集团旗下非全资附属公司惠升生物研发的司美格鲁肽注射液用于超重或肥胖的临床试验申请已获中国国家药监局受理。据悉，2023年司美格鲁肽全球总销售额已超两百亿美元，其中，司美格鲁肽注射液减重销售额约四十五亿美元，同比增长超400%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","BK1593","00460","HSCEI","BK1191","YANG","07226","BK1600","BK1515"],"gpt_icon":0},{"id":"2446387517","title":"四环医药(00460)：替格瑞洛分散片获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446387517","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446387517?lang=zh_cn&edition=full","pubTime":"2024-06-26 12:08","pubTimestamp":1719374882,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药 发布公告，集团附属公司弘和制药有限公司研发的替格瑞洛分散片(该产品)获得中华人民共和国(中国)国家药品监督管理局颁发的药品注册批件，可视同通过仿制药质量和疗效一致性评价。替格瑞洛分散片属于国家医保乙类产品。心脑血管领域为集团重点布局领域，本次替格瑞洛分散片获批上市，将进一步惠及广大患者，同时为集团的心脑血管领域药物管线再添一重要品种，对集团的经营业绩产生积极影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1593","BK1515","BK1600","BK1191","00460"],"gpt_icon":0},{"id":"2446538764","title":"四环医药(00460.HK)旗下抗血栓形成药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2446538764","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446538764?lang=zh_cn&edition=full","pubTime":"2024-06-26 12:01","pubTimestamp":1719374460,"startTime":"0","endTime":"0","summary":"四环医药(00460.HK) 公布，附属弘和制药研发的替格瑞洛分散片获得国家药监局颁发的药品注册批件，可视同通过仿制药质量和疗效一致性评价。弘和制药研发的该产品为国产首家获批上市。该药是一种新型抗血栓形成药，具有强效抗血小板聚预防血栓形成的作用。今次替格瑞洛分散片获批上市，将进一步惠及广大患者，同时为集团的心脑血管领域药物管线再添一重要品种，对集团的经营业绩产生积极影响。(ha/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-06-25 16:25。)AASTOCKS新闻","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220413154446706_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359288/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1191","BK1600","00460","BK1593"],"gpt_icon":0},{"id":"2445210650","title":"四环医药(00460.HK)6月24日耗资535.7万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2445210650","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445210650?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:33","pubTimestamp":1719225193,"startTime":"0","endTime":"0","summary":"格隆汇6月24日丨四环医药(00460.HK)公告，2024年6月24日，公司耗资535.7万港元回购1000万股，回购价格每股0.52-0.56港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062418332195d22ef7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062418332195d22ef7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00460","BK1593","BK1515","BK1600","BK1191"],"gpt_icon":0},{"id":"2445021749","title":"四环医药(00460)6月24日斥资535.7万港元回购1000万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2445021749","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445021749?lang=zh_cn&edition=full","pubTime":"2024-06-24 18:32","pubTimestamp":1719225146,"startTime":"0","endTime":"0","summary":"智通财经APP讯，四环医药(00460)发布公告，于2024年6月24日斥资535.7万港元回购股份1000万股，每股回购价格为0.52-0.56港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00460","BK1191","BK1593","BK1515","BK1600"],"gpt_icon":0},{"id":"2445321046","title":"四环医药(00460)出现大手买入300万股，成交价$0.52，涉资156万","url":"https://stock-news.laohu8.com/highlight/detail?id=2445321046","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445321046?lang=zh_cn&edition=full","pubTime":"2024-06-24 15:06","pubTimestamp":1719212760,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午03:06出现大手买入，成交量为300万，成交价为港币$0.52，涉资156万。至目前为止，股价跌7.273%，今日最高价为$0.55，而最低价为$0.51，总成交量为2.359千万股，总成交金额港币$1.24千万。","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2406245033/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1593","BK1515","BK1600","BK1191","00460"],"gpt_icon":0},{"id":"2445501836","title":"四环医药盘中异动 早盘急速跳水5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445501836","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445501836?lang=zh_cn&edition=full","pubTime":"2024-06-24 10:47","pubTimestamp":1719197241,"startTime":"0","endTime":"0","summary":"2024年06月24日早盘10时47分，四环医药股票出现波动，股价大幅跳水5.45%。截至发稿，该股报0.520港元/股，成交量745.7万股，换手率0.08%，振幅5.45%。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。四环医药股票所在的药品行业中，整体跌幅为0.10%。其相关个股中，精优药业、兆科眼科-B、亿胜生物科技涨幅较大，振幅较大的相关个股有君圣泰医药-B、中生联合、联康生物科技集团，振幅分别为28.13%、12.90%、8.96%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240624104721aef63408&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240624104721aef63408&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1600","BK1191","00460"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sihuanpharm.com.cn","stockEarnings":[{"period":"1week","weight":0.0182},{"period":"1month","weight":0.0182},{"period":"3month","weight":0.098},{"period":"6month","weight":0},{"period":"1year","weight":-0.2432},{"period":"ytd","weight":-0.1385}],"compareEarnings":[{"period":"1week","weight":-0.0211},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.048},{"period":"6month","weight":0.1092},{"period":"1year","weight":-0.0755},{"period":"ytd","weight":0.0345}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事研发、制造及销售药品。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其心脑血管产品包括克林澳、安捷利及欧迪美等。其非心脑血管产品包括仁澳、甲硝唑及罗沙替丁等。","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.124332},{"month":2,"riseRate":0.571429,"avgChangeRate":0.002088},{"month":3,"riseRate":0.357143,"avgChangeRate":-0.025475},{"month":4,"riseRate":0.538462,"avgChangeRate":0.029528},{"month":5,"riseRate":0.384615,"avgChangeRate":-0.005604},{"month":6,"riseRate":0.538462,"avgChangeRate":-0.006553},{"month":7,"riseRate":0.538462,"avgChangeRate":-0.001522},{"month":8,"riseRate":0.416667,"avgChangeRate":-0.027927},{"month":9,"riseRate":0.083333,"avgChangeRate":-0.082523},{"month":10,"riseRate":0.583333,"avgChangeRate":0.030986},{"month":11,"riseRate":0.538462,"avgChangeRate":0.020616},{"month":12,"riseRate":0.461538,"avgChangeRate":-0.01024}],"exchange":"SEHK","name":"四环医药","nameEN":"SIHUAN PHARM"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"四环医药,00460,四环医药股票,四环医药股票老虎,四环医药股票老虎国际,四环医药行情,四环医药股票行情,四环医药股价,四环医药股市,四环医药股票价格,四环医药股票交易,四环医药股票购买,四环医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"四环医药(00460)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供四环医药(00460)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}